As outlined in the information dated January 24, 2025, our company is collaborating with the Institute of Medical Science at the University of Tokyo (hereinafter referred to as “the Institute”) to undertake research on the mechanisms of cancer pathogenesis and progression.
In conjunction with this effort, we are advancing the development of future technology that enables the analysis of “cancer information” present in the blood during the early stages of cancer in a non-contact and non-invasive manner. This approach aims to reduce the burden on subjects and increase screening rates, thereby contributing to cancer prevention and early medical intervention. We have reached an agreement with the research team at the Institute on this objective.
As part of this endeavor, the research team at the Institute, focusing on our future technology, has requested our cooperation in data analysis for the preparation of a paper on the latest cancer research, leading to a collaborative effort.